Linked Life Data

11955653

Source:http://linkedlifedata.com/resource/pubmed/id/11955653

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2002-4-16
pubmed:abstractText
The aim of this Phase I, dose-escalation study was to determine the maximum tolerated dose (MTD), recommended dose (RD), and dose-limiting toxicity (DLT) of a raltitrexed ('Tomudex') and cisplatin combination in patients with previously untreated, metastatic non-small cell lung cancer (NSCLC).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0169-5002
pubmed:author
pubmed:issnType
Print
pubmed:volume
36
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
183-9
pubmed:dateRevised
2010-3-24
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
Phase I dose-escalating study of raltitrexed ('Tomudex') and cisplatin in metastatic non-small cell lung cancer.
pubmed:affiliation
Thorax-Klinik Heidelberg GmbH, Innere Medizin/Onkologie, Amalienstr. 5, Germany. prof.manegold@t-online.de
pubmed:publicationType
Journal Article, Clinical Trial, Clinical Trial, Phase I